These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. p53 protein overexpression and gene mutation in mixed Müllerian tumors of the uterus. Soong R; Knowles S; Hammond IG; Michael C; Iacopetta BJ Cancer Detect Prev; 1999; 23(1):8-12. PubMed ID: 9892985 [TBL] [Abstract][Full Text] [Related]
28. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Muto MG; Welch WR; Mok SC; Bandera CA; Fishbaugh PM; Tsao SW; Lau CC; Goodman HM; Knapp RC; Berkowitz RS Cancer Res; 1995 Feb; 55(3):490-2. PubMed ID: 7834614 [TBL] [Abstract][Full Text] [Related]
29. Establishment and characterization of a human cell line derived from a uterine papillary serous carcinoma with wild-type p53 function. Hashimoto H; Kojima A; Sudo T; Ohki N; Yamaguchi S; Mikami Y; Ito M; Nishimura R Hum Cell; 2008 Aug; 21(3):64-9. PubMed ID: 18667022 [TBL] [Abstract][Full Text] [Related]
30. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605 [TBL] [Abstract][Full Text] [Related]
31. Uterine papillary serous carcinoma--the KK Hospital experience. Ho TH; Lim TL; Tan HS Ann Acad Med Singap; 1998 Sep; 27(5):640-4. PubMed ID: 9919332 [TBL] [Abstract][Full Text] [Related]
32. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Memarzadeh S; Holschneider CH; Bristow RE; Jones NL; Fu YS; Karlan BY; Berek JS; Farias-Eisner R Int J Gynecol Cancer; 2002; 12(5):454-8. PubMed ID: 12366662 [TBL] [Abstract][Full Text] [Related]
33. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of a region on chromosome 1p in ovarian serous carcinoma that is frequently deleted in uterine papillary serous carcinoma. Herzog TJ; Kowalski LD; Liu H; Arlt M; Swisher E Gynecol Oncol; 2001 Jul; 82(1):139-42. PubMed ID: 11426975 [TBL] [Abstract][Full Text] [Related]
35. p53 mutations and overexpression in locally advanced breast cancers. Faille A; De Cremoux P; Extra JM; Linares G; Espie M; Bourstyn E; De Rocquancourt A; Giacchetti S; Marty M; Calvo F Br J Cancer; 1994 Jun; 69(6):1145-50. PubMed ID: 8198984 [TBL] [Abstract][Full Text] [Related]
36. p53 protein overexpression in smooth muscle tumors of the uterus. Niemann TH; Raab SS; Lenel JC; Rodgers JR; Robinson RA Hum Pathol; 1995 Apr; 26(4):375-9. PubMed ID: 7705814 [TBL] [Abstract][Full Text] [Related]
37. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788 [TBL] [Abstract][Full Text] [Related]
38. p53 mutation is infrequent in clear cell carcinoma of the ovary. Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858 [TBL] [Abstract][Full Text] [Related]
39. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477 [TBL] [Abstract][Full Text] [Related]